This site is intended for health professionals only

New once-monthly injectable treatment for schizophrenia

Janssen today announced the launch of XEPLION® (paliperidone palmitate), a new once-monthly, long-acting injectable (LAI) antipsychotic available in the UK.

Paliperidone palmitate provides sustained and consistent symptom control and a reduced risk of relapse compared to placebo.2 It also offers clear practical features for people with schizophrenia, including the option of being delivered in the arm and simple, convenient administration.

People with schizophrenia who do not take their antipsychotic medication as prescribed (non-adherent) are up to five times more likely to relapse (experience a recurrence of symptoms) than those who adhere to treatment.

Furthermore, research suggests that approximately two thirds of people with schizophrenia are partially or fully non-adherent to antipsychotic therapy. Paliperidone palmitate has been shown to significantly lower relapse rates versus placebo2 and with about half the number of injections compared to risperdone long-acting injectable (the most commonly prescribed atypical LAI) provides a new option to help people stay on treatment and reduce the risk of relapse.
Marjorie Wallace, founder and Chief Executive of SANE, comments: “Preventing relapse in schizophrenia remains a key issue. Providing choice to patients in the care and treatment they receive is important in helping them manage their condition, yet despite being central to government health policy, for many it is still an unmet need. We welcome the greater choice offered by this new treatment. We also hope that with the cuts and reductions in mental health services, it will not mean that people see less of their clinical teams.”

Professor Richard Gray, Honorary Nurse Consultant and Professor of Research at the University of East Anglia comments, “Ensuring patients are on the right medication is critical in the management of schizophrenia, and not just in treating acute episodes but to prevent relapse and help patients get on with their lives. A new treatment which combines the convenience of being once-monthly with the option of being given the arm, can only be of benefit to both people with schizophrenia and healthcare professionals alike.”